Start typing to search

Search through charts, companies, users, and news

⬆

⬇

Navigate

ESC

↵

Open

⌘

↵

Open in new tab

Lixte Biotechnology Holdings Inc

#138 in public LIXT.US public

https://newhedge.io/api/v2/companies/lixte-biotechnology-holdings-inc/bitcoin-acquisitions

API Documentation

API Access Required

API access is available with our Advanced plan.

Bitcoin Holdings

Total Bitcoin ₿ 10.5 BTC

% of 21M Supply 0.0%

Current Value $647,740

Cost Basis $1,196,832

ROI -45.88%

% of Company 0.6%

mNAV

174.4x

BTC/Share ₿ 0.00000096 BTC

Market Cap $115,619,896

Enterprise Value $116,215,314

Latest Purchase Sep 10, 2025

Avg. cost / BTC $113,984

Lixte Biotechnology Holdings Inc Stock Priced in BTC

0.000105 BTC

Lixte Biotechnology Holdings Inc Bitcoin Holdings Over Time

₿ 10.5 BTC

Bitcoin Acquisitions History

Type	BTC Change	Holdings	Transaction Value	Date
Buy	+0 BTC	0 BTC	$0	—
Buy	+0 BTC	0 BTC	$0	—
Buy	+0 BTC	0 BTC	$0	—
Buy	+0 BTC	0 BTC	$0	—
Buy	+0 BTC	0 BTC	$0	—
Get instant access to full data Register for free

Financial Highlights

Revenue (TTM) $0

Profit Margin 0%

Operating Margin 0%

ROE -101.95%

ROA -46.0%

EPS $-1.15

Book Value $0.902

Current Volume 419,194

Avg Volume (30d) 142,846

Volume vs Avg 2.93x

Lixte Biotechnology Holdings Inc Stock Price vs Bitcoin

$6.65 / $61,689

Company Overview

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Boca Raton, Florida.

Sector Healthcare

Industry Biotechnology

Sub-Industry Biotechnology

Employees 3

Exchange NASDAQ

Fiscal Year End December

IPO Date September 2007

Website Visit Website

Stock Returns

Share Price $6.65

1W Return -7.77%

1M Return +34.89%

3M Return +164.94%

1Y Return +381.88%

1Y vs BTC +427.8%

52W High $7.50

% Down from 52W High -11.3%

Key Executives

Mr. Geordan G. Pursglove CEO, President & Chairman

Age: 38

Mr. Peter M. Stazzone Chief Financial Officer

Age: 74

Mr. Bastiaan van der Baan M.Sc. Chief Scientific Officer

Age: 54

Company Details

Address 433 Plaza Real, Boca Raton, FL, United States, 33432

Phone 631 830 7092

ISIN US5393192027

CIK 0001335105

Currency USD

Most Recent Quarter 2026-03-31

Growth Metrics

Earnings Growth (YoY) 0%

Revenue Growth (YoY) 0%

Balance Sheet (Q1 2026)

Total Assets $10,865,298

Total Liabilities $1,686,706

Total Equity $7,945,032

Cash & Equivalents $0

Total Debt $595,418

Current Assets $3,407,750

Current Liabilities $1,224,934

Long-term Debt $0

Additional Financials

Gross Profit $0

Revenue per Share $0

Diluted EPS (TTM) $-1.15

PEG Ratio 0

Outstanding Shares 10,889,000

EPS Estimates

Current Quarter $0

Current Year $0

Next Quarter $0

Next Year $0

Recent Insider Activity

Name	Title	Type	Shares	Price	Value	Date	SEC
Der Baan Bastiaan Jeroen Van	INSIDER	Buy	10,000	$2.80	$28,000	Oct 03, 2023
Get instant access to full data Register for free

Major Holders

Major Institutional Holders

Scotia Capital Inc

2.4341%

265,049 shares

Renaissance Technologies Corp

0.7995%

87,058 shares

Vanguard Group Inc

0.6442%

70,147 shares

Federation des caisses Desjardins du Quebec

0.5543%

60,358 shares

Geode Capital Management, LLC

0.5059%

55,087 shares

Citadel Advisors Llc

0.4862%

52,942 shares

Vanguard Capital Management, LLC

0.4253%

46,311 shares

Vanguard Fiduciary Trust Co

0.3012%

32,798 shares

Ethos Financial Group LLC

0.2133%

23,226 shares

XTX Topco Ltd

0.2015%

21,941 shares

Major Mutual Fund Holders

Vanguard Institutional Extnd Mkt Idx Tr

0.4958%

53,988 shares

Fidelity Extended Market Index

0.2441%

26,580 shares

Spartan Extended Market Index Pool F

0.0832%

9,060 shares

NT Ext Equity Mkt Index Fund - NL

0.0772%

8,406 shares

Fidelity Total Market Index

0.0732%

7,971 shares

Fidelity Series Total Market Index

0.0621%

6,762 shares

NT Ext Equity Mkt Idx Fd - DC - NL - T2

0.0605%

6,588 shares

Spartan Total Market Index Pool G

0.0366%

3,985 shares

Fidelity Nasdaq Composite Index

0.0067%

730 shares

Northern Trust Extended Eq Market Idx

0.0018%

196 shares

Frequently Asked Questions

Common questions about Lixte Biotechnology Holdings Inc's Bitcoin holdings

How much Bitcoin does Lixte Biotechnology Holdings Inc hold?

Lixte Biotechnology Holdings Inc currently holds 10.5 BTC, which represents 0.0% of the total Bitcoin supply (21 million). This makes them the 138th largest public Bitcoin holder.

What is the current value of Lixte Biotechnology Holdings Inc's Bitcoin holdings?

As of today, Lixte Biotechnology Holdings Inc's Bitcoin holdings are worth approximately $647,740. This represents 0.6% of the company's total market value.

What is Lixte Biotechnology Holdings Inc's average cost basis for Bitcoin?

Lixte Biotechnology Holdings Inc's average cost basis for their Bitcoin purchases is $1,196,832 per Bitcoin. Their current return on investment (ROI) is -45.88%.

When did Lixte Biotechnology Holdings Inc last buy Bitcoin?

Lixte Biotechnology Holdings Inc's most recent Bitcoin purchase was Sep 10, 2025. View purchase details

What type of company is Lixte Biotechnology Holdings Inc?

Lixte Biotechnology Holdings Inc is a public company in the Healthcare sector and Biotechnology industry with approximately 3 employees .

What is Lixte Biotechnology Holdings Inc's market capitalization?

Lixte Biotechnology Holdings Inc has a market capitalization of approximately $115,619,896 and annual revenue of $0 .

What is Lixte Biotechnology Holdings Inc's mNAV?

Lixte Biotechnology Holdings Inc's mNAV (Market-to-Net Asset Value) is 174.4x, comparing the company's market value to its Bitcoin holdings value. An mNAV of 1.0 means market value equals Bitcoin stash, while >1.0 indicates a premium for the company's Bitcoin strategy.

What is Lixte Biotechnology Holdings Inc's market cap and enterprise value?

Lixte Biotechnology Holdings Inc has a market capitalization of $115,619,896 and an enterprise value of $116,215,314. Enterprise value represents the total company value including debt and cash, providing a more complete valuation picture than market cap alone.